Digger Pharmaceuticals (688192.SH): The latest research data on Gao Ruizhe and Birelentinib was released at the 67th American Society of Clinical Hematology

Zhitong Finance App News, Dizhe Pharmaceutical (688192.SH) announced that at the 67th American Society of Clinical Hematology (ASH) conference, the company announced the latest research results of two of the world's first novel drugs independently developed by the company: the highly selective JAK1 inhibitor Gaorizhe® (generic name: golixitinib capsules) has made many new developments in the field of T-cell lymphoma, and the latest clinical data of the non-covalent Lyn/BTK dual-target inhibitor birelentinib (DZD8586) in the field of B-cell lymphoma treatment.

At this ASH conference, Dizhe announced the latest follow-up data for the study. At 50 mg of the recommended phase III dose (RP3D), ORR was 84.2%; tumor remission was observed in patients previously treated with BTK inhibitors, Bcl-2 inhibitors, or BTK degrading agents, and patients with classic BTK resistance mutations (C481X) or other BTK mutations (including kinase “inactivation” mutations); long-lasting anti-tumor efficacy and good safety. No new safety issues were found during follow-up.